Glucotrack, Inc.: 10-Q filed 2023-11-14
What Glucotrack, Inc. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 30 published measures, 82 facts as tagged in accession 0001493152-23-040961.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-14
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-040961 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Glucotrack, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 7,195,000 | USD | |
| At 2022-12-31 | 2,438,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,638,000 | USD | |
| At 2022-12-31 | 1,208,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,557,000 | USD | |
| At 2023-06-30 | 7,743,000 | USD | |
| At 2022-12-31 | 1,230,000 | USD | |
| At 2022-09-30 | 2,355,000 | USD | |
| At 2022-06-30 | 3,190,000 | USD | |
| At 2021-12-31 | 5,155,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 6,888,000 | USD | |
| At 2022-12-31 | 2,312,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,223,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,685,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -928,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -3,148,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -4,147,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -2,789,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 4,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 8,730,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | -4,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -107,441,000 | USD | |
| At 2022-12-31 | -101,901,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 22,968,663 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 20,032,634 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 15,473,521 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 15,468,279 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 22,968,663 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 20,032,634 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 15,473,521 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 15,468,279 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.1 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.28 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.06 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.2 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.1 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.28 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.06 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.2 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 17,000 | USD | |
| At 2022-12-31 | 40,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 260,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 274,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,224,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,687,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -929,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -3,145,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 7,169,000 | USD | |
| At 2022-12-31 | 2,379,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,454,000 | USD | |
| At 2022-12-31 | 1,013,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,249,000 | USD | |
| At 2022-12-31 | 672,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 2,224,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 4,687,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 929,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 3,145,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,693,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 2,962,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 434,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,363,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 20,892,193 | shares | |
| At 2022-12-31 | 15,500,730 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-13 | 855,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 34,000 | USD | |
| At 2022-12-31 | 17,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 184,000 | USD | |
| At 2022-12-31 | 195,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,217,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,668,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -929,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -3,112,000 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 2,223,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 5,540,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 928,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 3,148,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 531,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,725,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 495,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,782,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 21,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 19,000 | USD | 273 |
Inspect the source
- Entity
- Glucotrack, Inc. / CIK 0001506983
- Captured
- SEC response SHA-256
91f527d0410e6f1b0a32a3b43c134ea7cd7d1bc7628a5c4dcf15089cf98e8a12
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001506983.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))